BE881208A - Composition pharmaceutique pour le traitement de psoriasis et methode d'utilisation de celle-ci - Google Patents

Composition pharmaceutique pour le traitement de psoriasis et methode d'utilisation de celle-ci

Info

Publication number
BE881208A
BE881208A BE0/199011A BE199011A BE881208A BE 881208 A BE881208 A BE 881208A BE 0/199011 A BE0/199011 A BE 0/199011A BE 199011 A BE199011 A BE 199011A BE 881208 A BE881208 A BE 881208A
Authority
BE
Belgium
Prior art keywords
psoriasis
treatment
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BE0/199011A
Other languages
English (en)
Inventor
P Bey
M Jung
Original Assignee
Merrell Toraude & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Toraude & Co filed Critical Merrell Toraude & Co
Publication of BE881208A publication Critical patent/BE881208A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
BE0/199011A 1977-07-11 1980-01-17 Composition pharmaceutique pour le traitement de psoriasis et methode d'utilisation de celle-ci BE881208A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81476577A 1977-07-11 1977-07-11
US2875879A 1979-04-10 1979-04-10
US2875779A 1979-04-10 1979-04-10

Publications (1)

Publication Number Publication Date
BE881208A true BE881208A (fr) 1980-05-16

Family

ID=27363337

Family Applications (3)

Application Number Title Priority Date Filing Date
BE189191A BE868882A (fr) 1977-07-11 1978-07-10 Derives halogenomethyles d'alpha-aminoacides, leur preparation et leurs utilisations therapeutiques
BE0/199011A BE881208A (fr) 1977-07-11 1980-01-17 Composition pharmaceutique pour le traitement de psoriasis et methode d'utilisation de celle-ci
BE0/199012A BE881209A (fr) 1977-07-11 1980-01-17 Composition pharmaceutique pour lutter contre le taux de croissance des tumeurs et methode d'utilisation de celle-ci

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BE189191A BE868882A (fr) 1977-07-11 1978-07-10 Derives halogenomethyles d'alpha-aminoacides, leur preparation et leurs utilisations therapeutiques

Family Applications After (1)

Application Number Title Priority Date Filing Date
BE0/199012A BE881209A (fr) 1977-07-11 1980-01-17 Composition pharmaceutique pour lutter contre le taux de croissance des tumeurs et methode d'utilisation de celle-ci

Country Status (9)

Country Link
JP (1) JPS5419913A (fr)
AU (1) AU522660B2 (fr)
BE (3) BE868882A (fr)
CA (1) CA1091661A (fr)
CH (1) CH642055A5 (fr)
DE (1) DE2828739A1 (fr)
FR (1) FR2430418A1 (fr)
GB (1) GB2001960B (fr)
NL (2) NL190662C (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0228034A3 (en) * 1985-12-19 1990-05-09 Merrell Dow Pharmaceuticals Inc. Arginine and agmatine derivatives for treating protozoal infections
US6103220A (en) * 1998-01-23 2000-08-15 Levine; Martin Lysine decarboxylase inhibitors for the prevention and treatment of periodontal disease
US6187296B1 (en) 1998-01-23 2001-02-13 The Board Of Regents Of The University Of Oklahoma Lysine decarboxylase inhibitors for the prevention and treatment of periodontal disease
WO2004087083A3 (fr) * 2003-03-26 2005-05-26 Gillette Co Ralentissement de la pousse des poils

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399151A (en) 1980-06-16 1983-08-16 Merrell Dow Pharmaceuticals Inc. Method of inhibiting the growth of protozoa
SE460517B (sv) * 1980-06-16 1989-10-23 Merrell Pharma Inc Anvaendning av en foerening foer framstaellning av ett laekemedel foer behandling av infektioner orsakade av trypanosoma brucei
GB2083030B (en) * 1980-08-23 1984-03-07 Merrell Toraude & Co Fluorinated pentene diamine derivatives
JPS5791958A (en) * 1980-08-23 1982-06-08 Merrell Toraude & Co Fluorinated pentene diamine derivative
US4437873A (en) 1981-03-23 1984-03-20 Merrell Dow Pharmaceuticals Inc. Method of inhibiting algae
US4423073A (en) * 1981-08-19 1983-12-27 Merrell Toraude Et Compagnie Fluorinated diaminopentene derivatives
US4446151A (en) * 1981-08-19 1984-05-01 Merrell Toraude Et Compagnie Decarboxylase-inhibiting fluorinated pentane diamine derivatives
US4435425A (en) 1982-04-09 1984-03-06 Merrell Toraude Et Compagnie Fluorinated diaminobutane derivatives
ES2041815T3 (es) * 1988-02-05 1993-12-01 Merrell Dow Pharmaceuticals Inc. Un procedimiento para la obtencion de derivados de ornitina 5-sustituidos.
CA1319123C (fr) * 1988-08-31 1993-06-15 Andrew T. Au Methode de preparation de (-)-derives de substitution en 2 d'ornithines
WO2021209563A1 (fr) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Composés destinés à être utilisés dans le traitement d'infections virales par un coronavirus associé au syndrome respiratoire
CN120943886B (zh) * 2025-10-16 2026-01-30 浙江肽昇生物医药有限公司 一种三肽Fmoc-Pro-Pro-Pro-OH的合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR64495B (en) * 1977-06-01 1980-03-31 Merck & Co Inc Novel fluorinated amino acids

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0228034A3 (en) * 1985-12-19 1990-05-09 Merrell Dow Pharmaceuticals Inc. Arginine and agmatine derivatives for treating protozoal infections
US6103220A (en) * 1998-01-23 2000-08-15 Levine; Martin Lysine decarboxylase inhibitors for the prevention and treatment of periodontal disease
US6187296B1 (en) 1998-01-23 2001-02-13 The Board Of Regents Of The University Of Oklahoma Lysine decarboxylase inhibitors for the prevention and treatment of periodontal disease
WO2004087083A3 (fr) * 2003-03-26 2005-05-26 Gillette Co Ralentissement de la pousse des poils
US7015349B2 (en) 2003-03-26 2006-03-21 The Gillette Company Reduction of hair growth
US7345192B2 (en) 2003-03-26 2008-03-18 The Gillette Company Reduction of hair growth

Also Published As

Publication number Publication date
FR2430418A1 (fr) 1980-02-01
DE2828739A1 (de) 1979-02-01
NL190662B (nl) 1994-01-17
CA1091661A (fr) 1980-12-16
FR2430418B1 (fr) 1984-07-13
NL950027I2 (nl) 1997-06-02
CH642055A5 (de) 1984-03-30
BE868882A (fr) 1978-11-03
AU3732778A (en) 1980-01-03
NL950027I1 (nl) 1996-02-01
BE881209A (fr) 1980-05-16
NL190662C (nl) 1994-06-16
NL7807453A (nl) 1979-01-15
JPH0122259B2 (fr) 1989-04-25
JPS5419913A (en) 1979-02-15
GB2001960A (en) 1979-02-14
GB2001960B (en) 1982-02-24
AU522660B2 (en) 1982-06-17

Similar Documents

Publication Publication Date Title
BE851328A (fr) Composition pour le traitement de l'hypercholesterolemie
BE884917A (fr) Agent pour le traitement de theilerioses et son application
BE880905A (fr) Compositions influencant le systeme nerveux central et leur methode d'utilisation
BE876157Q (fr) Medicament pour le traitement de l'acne
BE866841A (fr) Procede de preparation d'imidazoazines et -diazines substituees et leur utilisation
BE881209A (fr) Composition pharmaceutique pour lutter contre le taux de croissance des tumeurs et methode d'utilisation de celle-ci
BE885290A (fr) Compositions pharmaceutiques pour le traitement des hyperlipidemies et des hyperlipoproteinemies
BE829859A (fr) Procedes et compositions pharmaceutiques pour le traitement de l'hypercholesterolemie
BE852095A (fr) Composition pharmaceutique pour le traitement de la leucemie et de tumeurs
FR2277591A1 (fr) Composition pharmaceutique pour la prevention et le traitement de l'alcoolisme
FR2558372B1 (fr) Composition medicamenteuse pour le traitement de l'acne
FR2340737A1 (fr) Composition pour le traitement de l'hypercholesterolemie
BE871753A (fr) Nouvelle utilisation therapeutique de l'acetyl-1-carnitine pour le traitement des affections cardiaques
BE856740A (fr) Nouvelle composition medicamenteuse pour le traitement de la lithiase biliaire
BE856957A (fr) Electrode pour traitement d'ionophorese
FR2433978B1 (fr) Traitement d'algues
FR2546530B1 (fr) Traitement de laitiers d'acierie en vue de leur utilisation en cimenterie
BE894228A (fr) Composition pharmaceutique pour le traitement de l'atherosclerose
BE842389A (fr) Composition pharmaceutique pour le traitement de l'hyperuricemie
RO65965A2 (fr) Composition medicamenteuse pour le traitement d'ulcere gastroduodenel
FR2562798B1 (fr) Agent pharmaceutique pour le traitement du psoriasis
BE869248A (fr) Compositions pharmaceutiques pour le traitement de l'hyperglucagonemie et/ou de l'hyperglycemie
BE892339A (fr) Agents pour le traitement d'affections cardiaques coronariennes
FR2310768A1 (fr) Medicament pour le traitement de l'alopecia senilis
FR2517203B1 (fr) Composition pour le traitement de l'acne

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: MERREL TORAUDE ET CIE

Effective date: 20000117